CoreAge Rx review

The $99 a month on CoreAge Rx's semaglutide page is a 12-month rate paid in full: $1,188 in a single charge. Tirzepatide's $149 works the same way, at $1,788 up front. That condition is not concealed, but it is nowhere near the price. Every store surface prints "Starting at $99 per month" with nothing attached to it. The qualifier lives in a footer disclaimer on CoreAge's own lander, which reads "Prices shown are starting at, based on a 12-month plan paid in full," and in the company's own January 22, 2026 press release, which says it offers "compounded semaglutide starting at $99 per month when paid annually and compounded tirzepatide at $149 per month when paid annually."

What a one-month buyer pays is not published anywhere. There is no plan ladder on the site. The "Start your visit" button hands you to an intake app whose page carries no prices at all, because plan selection sits behind the questionnaire. Reading the homepage, both product pages and the FAQ on August 28, 2026 turned up no month-to-month figure on any of them. So if you want to try CoreAge for four weeks, you will not learn what that costs until you are already partway through signing up.

The annual charge is genuinely all-in. CoreAge's press release describes "all consultation fees, medication, and overnight shipping in a single annual payment," and its FAQ answers "Do higher doses cost more?" with a flat "No." The follow-up answer is the one that matters more: "Whatever price you lock in at checkout stays the same for all future months, regardless of dose increases." Titration is where GLP-1 pricing often climbs, and a rate that holds as the dose goes up is worth real money across a year. The FAQ also rules out add-ons: "There are no membership fees, no auto-rebills, and no surprise charges. You only pay for the plan you select at checkout."

CoreAge does not claim all 50 states, and nobody quoting it should either. Its FAQ says the company "offers service in the United States only but based on the therapy and medication being prescribed, there may be restrictions based on state," and that this "will be disclosed and confirmed per therapy and as part of the intake process." The same FAQ names prescribers assigned specifically to California, Massachusetts, Rhode Island and Vermont, which reads as a state-by-state arrangement rather than blanket national coverage. Confirm your own state at intake before you plan a year around the price.

Everything sold here is compounded. There is no FDA-approved Wegovy or Zepbound route on the account and no oral or sublingual form, so a needle is part of the deal. The homepage, both product pages and the FAQ, all read on August 28, 2026, do not name the 503A or 503B pharmacy that fills the prescription. That is a dated silence rather than an accusation, but the pharmacy is the part of the arrangement that actually makes your drug, and it is a fair thing to ask about before the card comes out.

It suits someone who has already decided to stay on a GLP-1 for a year and can put $1,188 or $1,788 through in one go. At that commitment the arithmetic is good and the number stops moving for twelve months. It suits almost nobody who wants to test tolerance for four weeks first, because the trial price is unpublished, the advertised price requires the full year, and there is no way to compare the two without starting an intake.

CoreAge Rx ranks first here and pays a commission on referrals, which is precisely why the annual-prepay condition leads this review rather than the $99. Held to the same standard as everything else on this site, its headline lands in the same category as Trimi's twelve-month rate: a real price, on a real plan, that is not what a first-time buyer pays in month one. The difference is that Trimi prints the month-to-month figure beside it and CoreAge does not.